Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
Saved in:
| Main Authors: | Ai Chida, Yutaka Hasegawa, Toshie Segawa, Daisuke Yamabe, Hirotaka Yan, Yusuke Chiba, Hiraku Chiba, Hirofumi Kinno, Tomoyasu Oda, Yoshihiko Takahashi, Koji Nata, Yasushi Ishigaki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/crie/9514578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and Biochemical Features in a Case of Familial Hypocalciuric Hypercalcemia Type 3 with AP2S1 Gene Mutation in Codon Arg15His
by: Mohamed Aashiq, et al.
Published: (2020-01-01) -
Singular case report of familial hypocalciuric hypercalcemia: a rare diagnosis of hypercalcemia in the older people
by: Etienne Ojardias, et al.
Published: (2025-12-01) -
Case Reports of Patients Diagnosed with Familial Hypocalciuric Hypercalcemia, A Disorder That Should be Kept in Mind in Hypercalcemia Cases
by: Ayşe Derya Buluş, et al.
Published: (2022-09-01) -
Hypocalciuric Hypercalcemia due to Impaired Renal Tubular Calcium Excretion in a Type 2 Diabetic Patient
by: Sihao Yang, et al.
Published: (2017-01-01) -
A Novel Variant in the Calcium-Sensing Receptor Associated with Familial Hypocalciuric Hypercalcemia and Low-to-Normal PTH
by: Sachin K. Majumdar, et al.
Published: (2020-01-01)